Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both ...

Sarhan was moved by the success he saw in his fellow AA members who used Mounjaro, Eli Lilly's GLP-1 jab, and after he got a job at Caron, he began prescribing the drugs to patients who met the ...

Sarhan was moved by the success he saw in his fellow AA members who used Mounjaro, Eli Lilly's GLP-1 jab, and after he got a job at Caron, he began prescribing the drugs to patients who met the ...

A horde of Mounjaro users claim to have been left 'desperate' after the controversial weight loss drug left them battling crippling self confidence issues, all because of one side effect. The popular ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an analysis of LLY stock now.

Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...